Method for providing the information for selecting the drugs for treating EML4-ALK positive non-small cell lung cancer and compositions for treating non-small cell lung cancer resistant to ALK inhibitors

摘要

The present invention relates to a method for providing information for selecting a therapeutic agent for EML4-ALK-positive non-small cell lung cancer patients and a composition for treating ALK inhibitor-resistant non-small cell lung cancer. A method for providing information for selecting a treatment drug for EML4-ALK-positive non-small cell lung cancer patients, comprising measuring the expression level and methylation level, and a deoxycytidine analog or a pharmaceutically acceptable salt thereof as an active ingredient It relates to a composition for treating non-small cell lung cancer that has acquired resistance to an ALK inhibitor.